Nucleotide signalling during inflammation
By M. Idzko, D. Ferrari, H. Eltzschig. Nature, 2014
853 citations recorded by the source corpus.
Inflammatory conditions are associated with the extracellular release of nucleotides, particularly ATP. In the extracellular compartment, ATP predominantly functions as a signalling molecule through the activation of purinergic P2 receptors. Metabotropic P2Y receptors are G-protein-coupled, whereas ionotropic P2X receptors are ATP-gated ion channels. Here we discuss how signalling events through P2 receptors alter the outcomes of inflammatory or infectious diseases. Recent studies implicate a role for P2X/P2Y signalling in mounting appropriate inflammatory responses critical for host defence against invading pathogens or tumours. Conversely, P2X/P2Y signalling can promote chronic inflammation during ischaemia and reperfusion injury, inflammatory bowel disease or acute and chronic diseases of the lungs. Although nucleotide signalling has been used clinically in patients before, research indicates an expanding field of opportunities for specifically targeting individual P2 receptors for the treatment of inflammatory or infectious diseases.
Subfields: Obstetrics and Gynecology, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/4b4b9ff03d69647f61f2c4181072f01bd05c9f4a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
Citations in the corpus
- Ion Channels in Innate and Adaptive Immunity (2015, background): “Of the seven P2X receptor isoforms, P2RX1, P2RX2, P2RX4, and P2RX7 are expressed on innate and adaptive immune cells (59).”
- The P2X7 Receptor in Infection and Inflammation (2017, neutral): “…from antigen-driven T lymphocyte proliferation to T helper 1 (Th1) and Th2 cell differentiation, from neutrophil and macrophage chemotaxis to intracellular pathogen killing, and from NADPH-oxidase activation to IL-1b maturation and release (Junger, 2011; Idzko et al., 2014; Cekic and Linden, 2016).”
- Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, background): “flammatory processes, which can be suppressed by the inhibition of the purinergic signalling pathway (212,213).”